160 related articles for article (PubMed ID: 31865812)
1. Gastropathy in patients with Wilson disease.
Antczak-Kowalska M; Członkowska A; Litwin T; Nehring P; Niewada M; Przybyłkowski A
Scand J Gastroenterol; 2020 Jan; 55(1):14-17. PubMed ID: 31865812
[No Abstract] [Full Text] [Related]
2. D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease.
Członkowska A; Litwin T; Karliński M; Dziezyc K; Chabik G; Czerska M
Eur J Neurol; 2014 Apr; 21(4):599-606. PubMed ID: 24447648
[TBL] [Abstract][Full Text] [Related]
3. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
Gupta P; Choksi M; Goel A; Zachariah U; Sajith KG; Ramachandran J; Chandy G; Kurian G; Rebekah G; Eapen CE
Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal side effects in children with Wilson's disease treated with zinc sulphate.
Wiernicka A; Jańczyk W; Dądalski M; Avsar Y; Schmidt H; Socha P
World J Gastroenterol; 2013 Jul; 19(27):4356-62. PubMed ID: 23885147
[TBL] [Abstract][Full Text] [Related]
5. Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease.
Zhang J; Xiao L; Yang W
BMC Neurol; 2020 Jun; 20(1):255. PubMed ID: 32593295
[TBL] [Abstract][Full Text] [Related]
6. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients.
Dzieżyc K; Karliński M; Litwin T; Członkowska A
Eur J Neurol; 2014 Feb; 21(2):332-7. PubMed ID: 24313946
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha S; Taly AB
J Neurol Sci; 2008 Jan; 264(1-2):129-32. PubMed ID: 17765927
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
9. Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson's disease at diagnosis.
Diao SP; Zhuang YS; Huang YQ; Zhou ZH; Liu AQ; Hong MF
BMC Neurol; 2023 Feb; 23(1):89. PubMed ID: 36855079
[TBL] [Abstract][Full Text] [Related]
10. Zinc monotherapy is effective in Wilson's disease patients with mild liver disease diagnosed in childhood: a retrospective study.
Ranucci G; Di Dato F; Spagnuolo MI; Vajro P; Iorio R
Orphanet J Rare Dis; 2014 Mar; 9():41. PubMed ID: 24661374
[TBL] [Abstract][Full Text] [Related]
11. Childhood Wilson Disease: Bangladesh Perspective.
Rukunuzzaman M; Karim AB; Nurullah M; Sultana F; Mazumder MW; Rahman MA; Billah SB; Begum F; Oliullah M
Mymensingh Med J; 2017 Apr; 26(2):406-413. PubMed ID: 28588179
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
[TBL] [Abstract][Full Text] [Related]
13. Persistence with treatment for Wilson disease: a retrospective study.
Masełbas W; Członkowska A; Litwin T; Niewada M
BMC Neurol; 2019 Nov; 19(1):278. PubMed ID: 31718567
[TBL] [Abstract][Full Text] [Related]
14. Relapse following withdrawal of D-penicillamine from combination (D-penicillamine + zinc) therapy in hepatic Wilson disease.
Panda K; Lal BB; Sood V; Khanna R; Alam S
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1017-1026. PubMed ID: 38695602
[TBL] [Abstract][Full Text] [Related]
15. Zinc Therapy for Wilson Disease in Children in French Pediatric Centers.
Santiago R; Gottrand F; Debray D; Bridoux L; Lachaux A; Morali A; Lapeyre D; Lamireau T
J Pediatr Gastroenterol Nutr; 2015 Dec; 61(6):613-8. PubMed ID: 26230903
[TBL] [Abstract][Full Text] [Related]
16. [Oral zinc in Wilson disease--an alternative to D-penicillamine].
Ramadori G; Keidl E; Hütteroth T; Dormeyer HH; Manns M; Meyer zum Büschenfelde KH
Z Gastroenterol; 1985 Jan; 23(1):25-9. PubMed ID: 4060799
[TBL] [Abstract][Full Text] [Related]
17. Response to different therapeutic approaches in Wilson disease. A long-term follow up study.
Rodríguez B; Burguera J; Berenguer M
Ann Hepatol; 2012; 11(6):907-14. PubMed ID: 23109455
[TBL] [Abstract][Full Text] [Related]
18. Spatial investigation of the elemental distribution in Wilson's disease liver after d-penicillamine treatment by LA-ICP-MS.
Hachmöller O; Zibert A; Zischka H; Sperling M; Groba SR; Grünewald I; Wardelmann E; Schmidt HH; Karst U
J Trace Elem Med Biol; 2017 Dec; 44():26-31. PubMed ID: 28965585
[TBL] [Abstract][Full Text] [Related]
19. Histologic evolution and long-term outcome of Wilson's disease: results of a single-center experience.
Sini M; Sorbello O; Sanna F; Battolu F; Civolani A; Fanni D; Faa G; Demelia L
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):111-7. PubMed ID: 23011036
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation.
Bruha R; Marecek Z; Pospisilova L; Nevsimalova S; Vitek L; Martasek P; Nevoral J; Petrtyl J; Urbanek P; Jiraskova A; Ferenci P
Liver Int; 2011 Jan; 31(1):83-91. PubMed ID: 20958917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
